Logo image of CMND

CLEARMIND MEDICINE INC (CMND) Stock Fundamental Analysis

NASDAQ:CMND - Nasdaq - CA1850534027 - Common Stock - Currency: USD

0.9  -0.05 (-5.26%)

After market: 0.9 0 (0%)

Fundamental Rating

1

Overall CMND gets a fundamental rating of 1 out of 10. We evaluated CMND against 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of CMND have multiple concerns. CMND is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CMND has reported negative net income.
In the past year CMND has reported a negative cash flow from operations.
CMND had negative earnings in each of the past 5 years.
In the past 5 years CMND always reported negative operating cash flow.
CMND Yearly Net Income VS EBIT VS OCF VS FCFCMND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

CMND's Return On Assets of -75.30% is on the low side compared to the rest of the industry. CMND is outperformed by 69.23% of its industry peers.
The Return On Equity of CMND (-173.75%) is worse than 66.67% of its industry peers.
Industry RankSector Rank
ROA -75.3%
ROE -173.75%
ROIC N/A
ROA(3y)-350.52%
ROA(5y)-233.83%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CMND Yearly ROA, ROE, ROICCMND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

CMND does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMND Yearly Profit, Operating, Gross MarginsCMND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, CMND has more shares outstanding
CMND has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CMND is higher compared to a year ago.
CMND Yearly Shares OutstandingCMND Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
CMND Yearly Total Debt VS Total AssetsCMND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

Based on the Altman-Z score of -6.31, we must say that CMND is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CMND (-6.31) is worse than 64.62% of its industry peers.
CMND has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
CMND has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: CMND outperforms 60.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.31
ROIC/WACCN/A
WACCN/A
CMND Yearly LT Debt VS Equity VS FCFCMND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M -6M

2.3 Liquidity

A Current Ratio of 1.72 indicates that CMND should not have too much problems paying its short term obligations.
CMND has a Current ratio of 1.72. This is in the lower half of the industry: CMND underperforms 65.64% of its industry peers.
A Quick Ratio of 1.72 indicates that CMND should not have too much problems paying its short term obligations.
CMND's Quick ratio of 1.72 is on the low side compared to the rest of the industry. CMND is outperformed by 61.03% of its industry peers.
Industry RankSector Rank
Current Ratio 1.72
Quick Ratio 1.72
CMND Yearly Current Assets VS Current LiabilitesCMND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 95.72% over the past year.
EPS 1Y (TTM)95.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CMND reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMND Price Earnings VS Forward Price EarningsCMND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMND Per share dataCMND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CMND does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLEARMIND MEDICINE INC

NASDAQ:CMND (6/10/2025, 4:04:11 PM)

After market: 0.9 0 (0%)

0.9

-0.05 (-5.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners13.98%
Inst Owner Change-1.8%
Ins Owners8.07%
Ins Owner Change0%
Market Cap4.62M
AnalystsN/A
Price TargetN/A
Short Float %3.3%
Short Ratio0.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.62
P/tB 1.68
EV/EBITDA N/A
EPS(TTM)-1.32
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.91
FCFYN/A
OCF(TTM)-0.91
OCFYN/A
SpS0
BVpS0.56
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -75.3%
ROE -173.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-350.52%
ROA(5y)-233.83%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.72
Quick Ratio 1.72
Altman-Z -6.31
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.51%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.21%
OCF growth 3YN/A
OCF growth 5YN/A